Advertisement
Advertisement

Read Now: News and Research From IDWeek 2014

Medical News

Antiviral Therapy for Prevention of Hepatocellular Carcinoma in Chronic Hepatitis C: Systematic Review and Meta-Analysis of Randomised Controlled Trials

October 31, 2012

Researchers at Copenhagen University, Denmark, conducted a systematic review and meta-analysis of randomized controlled trials to determine whether antiviral therapy for treatment of the hepatitis C virus (HCV) infection reduces the risk of developing hepatocellular carcinoma (liver cancer). Researchers performed electronic searches of the Cochrane Library, PubMed, EMBASE, and Web of Science for studies that met their requirements. They performed additional searches, including scanning reference lists from relevant papers on chronic hepatitis C and liver cancer, conference proceedings, and the World Health Organization Trial Search Portal.

Eight randomized trials, and five prospective cohort studies comparing antiviral therapy (interferon or pegylated interferon alone or with ribavirin), placebo, or no intervention were analyzed. The treatment time varied from 1 to 5 years and follow-up ranged from 2 to 8.7 years.

The results indicate that antiviral therapy may reduce the risk of liver cancer in hepatitis C-related fibrosis and cirrhosis. The effect may be seen irrespective of the virological response, but is more pronounced among virological responders compared with non-responders.

The study was reported online in the journal BMJ Open 2012;2:e001313 doi:10.1136/bmjopen-2012-001313.

Back to other news for October 2012

Adapted from:
BMJ Open
10.22.2012; Nina Kimer; Emilie Kristine Dahl; Lise Lotte Gluud; Aleksander Krag




This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
 

No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Advertisement